129 related articles for article (PubMed ID: 19889615)
1. Premedication with 20 mg dexamethasone effectively prevents relapse of extensive skin rash associated with gemcitabine monotherapy.
Kanai M; Matsumoto S; Nishimura T; Matsumura Y; Hatano E; Mori A; Masui T; Kawaguchi Y; Nakamura E; Tada S; Kitano T; Ishiguro H; Yanagihara K; Chiba T
Ann Oncol; 2010 Jan; 21(1):189-90. PubMed ID: 19889615
[No Abstract] [Full Text] [Related]
2. Gemcitabine induced skin rash.
Dua V; Goyal H
Indian Pediatr; 2013 Apr; 50(4):430. PubMed ID: 23665611
[No Abstract] [Full Text] [Related]
3. [Clinical analysis of premedication regimen with dexamethasone at different doses for docetaxel-induced hypersensitivity reaction].
Zhang MJ; Chen ZD; Pan YY
Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):795. PubMed ID: 20021838
[No Abstract] [Full Text] [Related]
4. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review.
Pentsova E; Liu A; Rosenblum M; O'Reilly E; Chen X; Hormigo A
J Neurooncol; 2012 Jan; 106(1):15-21. PubMed ID: 21811892
[TBL] [Abstract][Full Text] [Related]
5. Erysipeloid rash: A rare adverse event induced by gemcitabine.
Ruiz-Casado A; Gutiérrez D; Juez I
J Cancer Res Ther; 2015; 11(4):1024. PubMed ID: 26881588
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids.
Sakurada T; Kakiuchi S; Tajima S; Horinouchi Y; Konaka K; Okada N; Nishisako H; Nakamura T; Teraoka K; Kawazoe K; Yanagawa H; Nishioka Y; Ishizawa K
Biol Pharm Bull; 2015; 38(11):1752-6. PubMed ID: 26521826
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
Van Cutsem E; Li CP; Nowara E; Aprile G; Moore M; Federowicz I; Van Laethem JL; Hsu C; Tham CK; Stemmer SM; Lipp R; Zeaiter A; Fittipaldo A; Csutor Z; Klughammer B; Meng X; Ciuleanu T
Br J Cancer; 2014 Nov; 111(11):2067-75. PubMed ID: 25247318
[TBL] [Abstract][Full Text] [Related]
8. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
Westphalen CB; Kukiolka T; Garlipp B; Hahn L; Fuchs M; Malfertheiner P; Reiser M; Kütting F; Heinemann V; Beringer A; Waldschmidt DT
BMC Cancer; 2020 Feb; 20(1):155. PubMed ID: 32093649
[TBL] [Abstract][Full Text] [Related]
9. [Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer].
Sumii T; Funakoshi A; Ito T; Mizumoto K; Tanaka M; Migita Y; Sakai T; Shinozaki H; Yamaguchi H; Niyahara T; Muranaka T; Eriguchi N; Ueki T;
Gan To Kagaku Ryoho; 2003 Jul; 30(7):971-6. PubMed ID: 12894712
[TBL] [Abstract][Full Text] [Related]
10. A rash diagnosis: Gemcitabine-associated pseudocellulitis.
Strouse C; Epperla N
J Oncol Pharm Pract; 2017 Mar; 23(2):157-160. PubMed ID: 26946530
[TBL] [Abstract][Full Text] [Related]
11. Anal pruritus after cancer chemotherapy with gemcitabine.
Hejna M; Valencak J; Raderer M
N Engl J Med; 1999 Feb; 340(8):655-6. PubMed ID: 10049089
[No Abstract] [Full Text] [Related]
12. Intravenous fluid therapy successfully prevents renal injury by gemcitabine in patients with pancreatic cancer.
Ko SB; Azuma S; Kamimura K; Goto H; Anzai N; Yamamoto A; Ishiguro H; Mizuno N
Pancreas; 2011 Jul; 40(5):784-6. PubMed ID: 21673540
[No Abstract] [Full Text] [Related]
13. Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Boeck S; Hausmann A; Reibke R; Schulz C; Heinemann V
Anticancer Drugs; 2007 Oct; 18(9):1109-11. PubMed ID: 17704662
[TBL] [Abstract][Full Text] [Related]
14. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Aranda E; Manzano JL; Rivera F; Galán M; Valladares-Ayerbes M; Pericay C; Safont MJ; Mendez MJ; Irigoyen A; Arrivi A; Sastre J; Díaz-Rubio E
Ann Oncol; 2012 Jul; 23(7):1919-25. PubMed ID: 22156621
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E;
Eur J Cancer; 2017 Apr; 75():73-82. PubMed ID: 28222309
[TBL] [Abstract][Full Text] [Related]
16. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Wacker B; Nagrani T; Weinberg J; Witt K; Clark G; Cagnoni PJ
Clin Cancer Res; 2007 Jul; 13(13):3913-21. PubMed ID: 17606725
[TBL] [Abstract][Full Text] [Related]
17. Characteristic distribution of maculopapular rash caused by gemcitabine-based chemotherapy.
Tohyama M; Asagi A; Nakasya A; Iuchi S; Hashine K
J Dermatol; 2021 Feb; 48(2):215-218. PubMed ID: 33179309
[TBL] [Abstract][Full Text] [Related]
18. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting.
Stepanski EJ; Reyes C; Walker MS; Satram-Hoang S; Leon L; Wojtowicz-Praga S; Miller PJ; Houts AC; Schwartzberg LS
Pancreas; 2013 Jan; 42(1):32-6. PubMed ID: 22699203
[TBL] [Abstract][Full Text] [Related]
19. Livedo reticularis as an initial clinical manifestation of gemcitabine-induced hemolytic uremic syndrome.
Zemtsov A; Omueti-Ayoade K; Zemtsov R; Yang M
J Dermatol; 2012 May; 39(5):487-9. PubMed ID: 21906135
[No Abstract] [Full Text] [Related]
20. Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Fleming DR; Glisson SD; Bhupalam L; Michelson GD; Goldsmith GH; LaRocca RV
Am J Clin Oncol; 2000 Aug; 23(4):349-52. PubMed ID: 10955861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
